President Donald Trump said Tuesday that he would be in favor of Elon Musk or Larry Ellison purchasing TikTok and giving half ownership with the U.S. government.
Musk slammed a Trump-backed $500 billion AI joint venture building out OpenAI’s artificial general intelligence.
At a press conference capping his first full day back in the White House, Donald Trump stood beside three of the most influential executives in the world—Sam Altman of OpenAI, Larry Ellison of Oracle,
Elon Musk is clashing with OpenAI CEO Sam Altman over the Stargate artificial intelligence infrastructure project touted by President Donald Trump, the latest in a feud between the two billionaires that started on OpenAI’s board and is now testing Musk’s influence with the new presidential administration.
“They have to produce a lot of electricity and we will make it possible for them to get that production done very easily, at their own plants if they want,” Trump said. “At the AI plant they will build energy generation and that will be incredible.” It’s unclear if building energy operations inside an AI data center is possible in practice.
OpenAI CEO Sam Altman called Stargate, “the most important project for this era” and promised that all of the new investment his company was making would help cure diseases. Altman was actually prompted by Trump to talk about the medical advances that AI would supposedly figure out.
President Donald Trump talked up a joint venture investing up to $500 billion for infrastructure tied to AI by a new partnership formed by OpenAI, Oracle and SoftBank.
US tech titans Elon Musk, Mark Zuckerberg and Jeff Bezos are taking a prominent place in the new Trump era, but another player from another era -- Oracle boss Larry Ellison -- is making a surprise return.
The Stargate project, led by OpenAI's Sam Altman - to build the "world's largest AI infrastructure" - was announced by Donald Trump at a special press conference at the White House. Elon Musk, however,
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.